Clinical implications of mutational analysis in gastrointestinal stromal tumours.
作者信息
Hoeben A, Schöffski P, Debiec-Rychter M
机构信息
Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University of Leuven, Leuven, Belgium.
出版信息
Br J Cancer. 2008 Feb 26;98(4):684-8. doi: 10.1038/sj.bjc.6604217. Epub 2008 Feb 5.
Abstract
The management of localised and advanced gastrointestinal stromal tumours (GISTs) in terms of histological diagnosis, surgery, imaging, medical treatment and molecular biology has rapidly changed since introduction of imatinib mesylate for molecularly targeted therapy in 2000. In this minireview, we briefly summarise and discuss the current data relevant to the increasing role of molecular characterisation of GISTs in the diagnosis, risk assessment and effective targeted therapy.
摘要
相似文献
1
Clinical implications of mutational analysis in gastrointestinal stromal tumours.
Br J Cancer. 2008 Feb 26;98(4):684-8. doi: 10.1038/sj.bjc.6604217. Epub 2008 Feb 5.
2
Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.
Cancer Invest. 2010 Oct;28(8):839-48. doi: 10.3109/07357907.2010.494322.
3
Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
Virchows Arch. 2007 Oct;451(4):743-9. doi: 10.1007/s00428-007-0473-9. Epub 2007 Aug 14.
4
Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.
Cancer Med. 2020 Sep;9(18):6485-6496. doi: 10.1002/cam4.3212. Epub 2020 Jul 22.
5
[Not Available].
Tidsskr Nor Laegeforen. 2018 Oct 1;138(15). doi: 10.4045/tidsskr.18.0200. Print 2018 Oct 2.
6
Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Pathol Res Pract. 2019 Dec;215(12):152708. doi: 10.1016/j.prp.2019.152708. Epub 2019 Oct 29.
7
V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
J Clin Pathol. 2009 Jul;62(7):613-6. doi: 10.1136/jcp.2009.064550.
8
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28.
9
PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features.
Histopathology. 2005 Feb;46(2):166-75. doi: 10.1111/j.1365-2559.2005.02061.x.
引用本文的文献
1
Phase II Study of Sunitinib in Tumors With Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
JCO Precis Oncol. 2024 Dec;8:e2400514. doi: 10.1200/PO-24-00514. Epub 2024 Dec 12.
2
Potential indicators predict progress after surgical resection of gastrointestinal stromal tumors.
Front Med. 2012 Sep;6(3):317-21. doi: 10.1007/s11684-012-0203-9. Epub 2012 Jul 14.
3
Cyclin H expression is increased in GIST with very-high risk of malignancy.
BMC Cancer. 2010 Jul 2;10:350. doi: 10.1186/1471-2407-10-350.
4
Solution structures of all parallel-stranded monomeric and dimeric G-quadruplex scaffolds of the human c-kit2 promoter.
Nucleic Acids Res. 2010 Oct;38(19):6757-73. doi: 10.1093/nar/gkq558. Epub 2010 Jun 21.
5
Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
Oncology. 2010;78(2):130-40. doi: 10.1159/000312655. Epub 2010 Apr 13.
6
Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study.
J Gastrointest Cancer. 2010 Mar;41(1):60-70. doi: 10.1007/s12029-009-9111-x.
7
A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics.
J Am Chem Soc. 2009 Sep 23;131(37):13399-409. doi: 10.1021/ja904007p.
8
The benefits of molecular pathology in the diagnosis of musculoskeletal disease : part I of a two-part review: soft tissue tumors.
Skeletal Radiol. 2010 Feb;39(2):105-15. doi: 10.1007/s00256-009-0759-x.
9
Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule.
J Med Chem. 2009 Jun 25;52(12):3774-83. doi: 10.1021/jm900424a.
10
The epidemiology and pathogenesis of neoplasia in the small intestine.
Ann Epidemiol. 2009 Jan;19(1):58-69. doi: 10.1016/j.annepidem.2008.10.004.
本文引用的文献
1
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Clin Cancer Res. 2007 Aug 15;13(16):4874-81. doi: 10.1158/1078-0432.CCR-07-0484.
2
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors.
Lab Invest. 2007 Oct;87(10):1029-41. doi: 10.1038/labinvest.3700628. Epub 2007 Jul 16.
3
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30.
4
Mutations in gastrointestinal stromal tumors--a population-based study from Northern Norway.
APMIS. 2007 Apr;115(4):289-98. doi: 10.1111/j.1600-0463.2007.apm_587.x.
5
The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hum Pathol. 2007 May;38(5):679-87. doi: 10.1016/j.humpath.2007.03.001.
6
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S30-4. doi: 10.3816/ccc.2006.s.005.
7
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Clin Cancer Res. 2007 Mar 1;13(5):1367-73. doi: 10.1158/1078-0432.CCR-06-2328.
8
Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
Lab Invest. 2007 Apr;87(4):365-71. doi: 10.1038/labinvest.3700524. Epub 2007 Jan 29.
9
Gastrointestinal stromal tumors: pathology and prognosis at different sites.
Semin Diagn Pathol. 2006 May;23(2):70-83. doi: 10.1053/j.semdp.2006.09.001.
10
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Gastroenterology. 2006 Dec;131(6):1734-42. doi: 10.1053/j.gastro.2006.09.017. Epub 2006 Sep 20.
Zotero 插件